Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BNGO
stocks logo

BNGO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
7.93M
-2.86%
-1.360
-82.41%
8.37M
+29.66%
-0.780
-32.17%
9.08M
+34.78%
-0.740
-62.81%
Estimates Revision
The market is revising Upward the revenue expectations for Bionano Genomics, Inc. (BNGO) for FY2025, with the revenue forecasts being adjusted by 0.12% over the past three months. During the same period, the stock price has changed by -57.39%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.12%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-11.27%
In Past 3 Month
Stock Price
Go Down
down Image
-57.39%
In Past 3 Month
Wall Street analysts forecast BNGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNGO is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast BNGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNGO is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.700
sliders
Low
8.00
Averages
8.00
High
8.00
Current: 1.700
sliders
Low
8.00
Averages
8.00
High
8.00
H.C. Wainwright
Buy
downgrade
$11 -> $7
2025-11-24
Reason
H.C. Wainwright
Price Target
$11 -> $7
2025-11-24
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Bionano Genomics to $7 from $11 and keeps a Buy rating on the shares. The firm adjusted the company's model post the Q3 report.
H.C. Wainwright
Buy
maintain
$10 -> $11
2025-08-18
Reason
H.C. Wainwright
Price Target
$10 -> $11
2025-08-18
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Bionano Genomics to $11 from $10 and keeps a Buy rating on the shares. The company demonstrated sequential revenue growth in Q2, the analyst tells investors in a research note.
Maxim
Jason McCarthy
Hold
to
Buy
upgrade
$8
2025-05-20
Reason
Maxim
Jason McCarthy
Price Target
$8
2025-05-20
upgrade
Hold
to
Buy
Reason
Maxim analyst Jason McCarthy upgraded Bionano Genomics to Buy from Hold with an $8 price target. The company has taken several steps to get itself back on track, including significant cost reductions, refocusing on its core optical genome mapping business, shifting focus from customer acquisition to expanding utilization, and securing cash runway into Q1 of FY26, the analyst tells investors in a research note. Optical genome mapping is also gaining traction at leading institutions, seeing real-world use, and generating publications, the firm adds.
HC Wainwright & Co.
Yi Chen
Strong Buy
Initiates
$10
2025-04-09
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$10
2025-04-09
Initiates
Strong Buy
Reason
Scotiabank
Sung Ji Nam
Hold
Maintains
$1 → $4
2025-04-02
Reason
Scotiabank
Sung Ji Nam
Price Target
$1 → $4
2025-04-02
Maintains
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Bionano Genomics Inc (BNGO.O) is -0.51, compared to its 5-year average forward P/E of -6.78. For a more detailed relative valuation and DCF analysis to assess Bionano Genomics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.78
Current PE
-0.51
Overvalued PE
3.58
Undervalued PE
-17.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.47
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
5.20
Undervalued EV/EBITDA
-18.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
23.21
Current PS
0.00
Overvalued PS
61.73
Undervalued PS
-15.31
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BNGO News & Events

Events Timeline

(ET)
2025-12-03
08:10:00
Bionano Laboratories Sees 47% Increase in Payment for CPT Code 81195 to $1853.22
select
2025-11-06 (ET)
2025-11-06
08:25:40
Bionano Genomics Reveals Study Findings on OGM Publication
select
2025-09-16 (ET)
2025-09-16
09:11:25
Bionano Genomics sets public offering price at $2.00 for 5 million shares
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
12-03Newsfilter
Bionano Laboratories Sees 47% Increase in 2026 CLFS for OGM Testing
  • Fee Increase: Bionano Laboratories' CPT code 81195 sees a 47% increase in the 2026 Clinical Laboratory Fee Schedule, rising from $1,263.53 to $1,853.22, which will significantly enhance reimbursement for OGM testing related to blood cancers, thereby strengthening market competitiveness.
  • Committee Support: The Clinical Diagnostic Laboratory Test Committee unanimously voted 10-0 in favor of reconsidering the payment standard for CPT code 81195, indicating strong industry recognition and confidence in OGM technology.
  • Market Impact: The new pricing is expected to make Bionano's OGM-Dx™ product line more attractive, likely driving market share growth in hematologic malignancy testing and further solidifying its leadership position in genome analysis.
  • Global Recognition: Bionano's Chief Medical Officer stated that the new payment level will not only facilitate the promotion of OGM testing in the U.S. market but also enhance global awareness of OGM applications in oncology and clinical genetic testing.
[object Object]
Preview
4.0
11-24Benzinga
Baidu Expected to Surge Over 69%: 10 Leading Analyst Predictions for Monday

  • Analyst Upgrades and Price Target Increases: JP Morgan upgraded Cipher Mining Inc and Baidu Inc, raising their price targets significantly, while B of A Securities upgraded Barrick Mining Corp's rating and price target as well.

  • Analyst Downgrades and Price Target Reductions: HC Wainwright & Co. downgraded BioNano Genomics Inc, and Jefferies downgraded Exact Sciences Corp despite increasing their price targets.

  • Mixed Analyst Ratings: Various analysts maintained or adjusted ratings for companies like Mp Materials Corp and Flutter Entertainment PLC, with some upgrades and downgrades occurring simultaneously.

  • Current Stock Prices: The article provides the latest closing prices for the mentioned stocks, indicating market performance and analyst sentiment.

[object Object]
Preview
8.5
09-21Yahoo Finance
Bionano Genomics Initiates $10 Million Public Offering

  • Public Offering Announcement: Bionano Genomics, Inc. has launched a public offering of 5 million shares at $2.00 each, aiming to raise $10 million, with potential additional funds of $20 million if warrants are fully exercised.

  • Strategic Focus and Growth Plans: The company is enhancing utilization of its optical genome mapping and VIA software, aiming to expand into clinical and anatomic pathology while developing reimbursement support to increase profits and reduce costs.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Bionano Genomics Inc (BNGO) stock price today?

The current price of BNGO is 1.7 USD — it has decreased -1.73 % in the last trading day.

arrow icon

What is Bionano Genomics Inc (BNGO)'s business?

Bionano Genomics, Inc. is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

arrow icon

What is the price predicton of BNGO Stock?

Wall Street analysts forecast BNGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNGO is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Bionano Genomics Inc (BNGO)'s revenue for the last quarter?

Bionano Genomics Inc revenue for the last quarter amounts to 7.37M USD, increased 21.31 % YoY.

arrow icon

What is Bionano Genomics Inc (BNGO)'s earnings per share (EPS) for the last quarter?

Bionano Genomics Inc. EPS for the last quarter amounts to -1.59 USD, decreased -94.86 % YoY.

arrow icon

What changes have occurred in the market's expectations for Bionano Genomics Inc (BNGO)'s fundamentals?

The market is revising Upward the revenue expectations for Bionano Genomics, Inc. (BNGO) for FY2025, with the revenue forecasts being adjusted by 0.12% over the past three months. During the same period, the stock price has changed by -57.39%.
arrow icon

How many employees does Bionano Genomics Inc (BNGO). have?

Bionano Genomics Inc (BNGO) has 98 emplpoyees as of December 05 2025.

arrow icon

What is Bionano Genomics Inc (BNGO) market cap?

Today BNGO has the market capitalization of 17.30M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free